Trader: Low Volume ...
Arqule Inc. (ARQL: NASDAQ)
$5.68 0.15 | 2.71%
06/04/12 - 04:00 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -10.76M | -30.13M | -36.14M | -50.86M |
| Operating Gains/Losses | -20.00K | 712.00K | -1.59M | -6.67M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -4.90M | 4.48M | -1.90M | 98.00K |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | -78.00K | 0.00 |
| (Increase) Decrease In Other Working Capital | -10.72M | -16.49M | -5.84M | 69.36M |
| Other Non-Cash Items | 3.83M | 2.71M | 2.88M | 13.72M |
| Net Cash From Continuing Operations | -23.74M | -34.82M | -41.76M | 27.47M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -23.74M | -34.82M | -41.76M | 27.47M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 94.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 149.72M | 154.13M | 32.10M | 67.47M |
| Purchases of Property, Plant & Equipment | -594.00K | -357.00K | -660.00K | -3.52M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -185.97M | -91.48M | -94.09M | -8.79M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -36.85M | 62.29M | -62.65M | 55.26M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 47.75M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 51.22M | 835.00K | 718.00K | 578.00K |
| Repayment of Long-Term Debt | 0.00 | -44.40M | -1.65M | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 51.22M | -43.56M | -932.00K | 48.33M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -9.36M | -16.09M | -105.34M | 131.06M |
Portfolios with ARQL
- Portfolio NameUser Type
- Contributor22 Biopharma Stocks With Br...
- UserGFNN Stockdiagnostics 11
- ContributorStocks Under-$10 Moving Hig...
- Contributor7 Cancer Drug Stocks to Kno...
- UserASCO 2010
- UserDano Boy's List
- User2bullmates Portfolio 1
- UserASCO 2009 Part 2 the end of...
- UserBVF Inc.
- UserASCO is coming...Papers rel...
Latest ARQL Headlines from TheStreet
- ASCO 2012 Live Blog -- Saturday 06.02.12 | 07:06 am
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- 3 Stocks Under $10 Moving Higher 04.03.12 | 12:04 pm
- 7 Cancer Drug Stocks to Know Right Now 03.14.12 | 09:03 am
- Arqule Inc. Stock Downgraded (ARQL) 11.15.11 | 06:11 am
- Arqule Inc. Stock Upgraded (ARQL) 05.10.11 | 07:05 am
- Stocks Under $10: Soaring Biotech Stock
01.19.11 | 08:01 am - Crystallex International, Sprint Nextel: Early Volume Plays 06.07.10 | 08:06 am
Press Releases for ARQL
- Positive Phase 2 Study Results For Tivantinib In Previously Treated Hepatocellular Carcinoma To Be Presented At ASCO - Business Wire 06.02.12 | 07:06 am
- ArQule, Inc. To Present At Jefferies 2012 Global Healthcare Conferences - Business Wire 05.31.12 | 08:05 am
- ArQule And Daiichi Sankyo Announce Completion Of Patient Recruitment In Phase 3 Clinical Trial Of Tivantinib In Non-Small Cell Lung Cancer - Business Wire 05.18.12 | 07:05 am
- Positive Phase 2 Clinical Data With Tivantinib In Hepatocellular Carcinoma To Be Highlighted In Oral Presentation At 2012 Annual Meeting Of American Society Of Clinical Oncology - Business Wire 05.17.12 | 07:05 am
- ArQule Reports First Quarter 2012 Financial Results - Business Wire 05.03.12 | 07:05 am
- ArQule To Report First Quarter 2012 Financial Results On May 3, 2012 - Business Wire 04.26.12 | 08:04 am
- ArQule Announces Completion Of Common Stock Offering With Full Exercise Of Option To Purchase Additional Shares - Business Wire 04.16.12 | 04:04 pm
- ArQule Prices Public Offering Of Common Stock - Business Wire 04.11.12 | 07:04 am
- ArQule Announces Proposed Public Offering - Business Wire 04.10.12 | 07:04 am
- ArQule Announces Presentations At AACR 102nd Annual Meeting - Business Wire 03.29.12 | 08:03 am
Partner Headlines for ARQL
- Stock Insights: Dendreon, Medtronic, FedEx, ArQule, Rentrak June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- ArQule Announces Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma - Benzinga 06.02.12 | 06:06 pm
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3 - Seeking Alpha 05.25.12 | 08:05 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 05.01.12 | 09:05 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 04.02.12 | 09:04 am
- Company News for January 18, 2012 - Corporate Summary - Zacks 01.18.12 | 10:01 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 11.15.11 | 09:11 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 10.04.11 | 09:10 am
- Drugs to Watch at ASCO 2011 - Seeking Alpha 06.02.11 | 08:06 am
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am





